urapidil has been researched along with Chronic Disease in 3 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 9.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 5.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "Urapidil was a much weaker coronary vasodilator than dipyridamole." | 1.29 | Global and regional haemodynamic effects of urapidil in conscious dogs with chronic coronary artery occlusion. ( Deruyter, HA; Flameng, W; Marcus, MA; Mignolet, K; Miserez, M; Van Aken, HK; van de Velde, M; Wouters, PF, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wouters, PF | 1 |
| Marcus, MA | 1 |
| Van Aken, HK | 1 |
| van de Velde, M | 1 |
| Miserez, M | 1 |
| Deruyter, HA | 1 |
| Mignolet, K | 1 |
| Flameng, W | 1 |
| Dorszewski, A | 1 |
| Göhmann, E | 1 |
| Dorsźewski, B | 1 |
| Werner, GS | 1 |
| Kreuzer, H | 1 |
| Figulla, HR | 1 |
| Wiechmann, HW | 1 |
2 trials available for urapidil and Chronic Disease
| Article | Year |
|---|---|
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Double-Blind Meth | 1997 |
[Hemodynamic effects of different antihypertensive combinations].
Topics: Acebutolol; Antihypertensive Agents; Captopril; Chronic Disease; Diuretics; Drug Evaluation; Drug Th | 1988 |
1 other study available for urapidil and Chronic Disease
| Article | Year |
|---|---|
Global and regional haemodynamic effects of urapidil in conscious dogs with chronic coronary artery occlusion.
Topics: Adrenergic alpha-Antagonists; Animals; Atrial Function, Left; Blood Pressure; Chronic Disease; Colla | 1994 |